Skip to main content
. Author manuscript; available in PMC: 2017 Jul 25.
Published in final edited form as: Nat Rev Clin Oncol. 2015 Dec 1;13(5):305–318. doi: 10.1038/nrclinonc.2015.210

Figure 1. Proposed treatment algorithm for patients aged >60 years with newly diagnosed AML.

Figure 1

All novel agents, both targeted and ‘non-targeted’, should be administered in the setting of a clinical trial. HDAC, histone deacetylase; LDAC, low‑dose cytarabine.